Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

Data from Phase 1 Single Agent and Phase 1b Combination Clinical Trials

Demonstrate Voreloxin's Anti-Leukemic Activity

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data Saturday from two clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), including updated results of a Phase 1 trial of voreloxin when used as a single agent in relapsed or refractory patients with acute myeloid leukemia (AML) and preliminary data from a Phase 1b trial of voreloxin in combination with cytarabine in patients with relapsed/refractory AML.

"Voreloxin has demonstrated anti-leukemic activity as a single agent and is showing encouraging early response data when administered in combination with cytarabine. Importantly, it has also been generally well tolerated, even among patients older than 60 and patients with AML with poor risk features," said Judith E. Karp, M.D., Director, Adult Leukemia Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and an investigator for the Phase 1 and Phase 1b clinical trials of voreloxin in AML. "Voreloxin appears to be a promising new drug for the treatment of AML and I look forward to the results of continued clinical investigation."

Analysis of Safety and Response Data for Older AML Patients Supports Phase 2 REVEAL-1 Trial

Researchers presented an analysis of comparative safety, pharmacokinetic and response data from Sunesis' Phase 1 dose-escalating trial of single-agent voreloxin comparing results from older patients (age >/= 60) with those from younger patients (age < 60). Overall, voreloxin demonstrates a similar safety profile in both older and you
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
(Date:7/10/2014)... those students looking to bump up their grade point ... more time in a library or study hall, but ... shows that students who were members of the recreational ... freshman and sophomore years had higher GPAs than those ... students with memberships stayed in school longer. An increase ...
(Date:7/10/2014)... A research review identifying the clinical indicators most strongly ... the process of developing evidence-based guidelines for concussion diagnosis, ... by Neurosurgery , official journal of ... journal is published by Lippincott Williams & Wilkins ... . , Based on analysis of the best ...
(Date:7/10/2014)... just as tempting as full-fat equivalents could be ... into how proteins can replace fats without affecting ... the Engineering and Physical Sciences Research Council (EPSRC), ... of Edinburgh has produced modified proteins that easily ... the behaviour of fats during food manufacture. The ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
Breaking Medicine News(10 mins):Health News:Want a higher GPA in college? Join a gym 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2
... ... today announced MathMagic Personal Edition 4.8, their award-winning multi-purpose equation editor. With a ... equation editor for mathematical equations and symbols. MathMagic reads and writes various industry ... Docs and Zoho Writer, and other enhanced features. , ...
... ... and cold therapy has been cited by the American Academy of Orthopedic Surgeons as an ... selection of compressive cold therapy systems for plantar fasciitis treatment as a complement to its ... ...
... PHILADELPHIA, Dec. 3 The American Red Cross won ... Teamsters, Local 929 after its members illegally blocked vehicles ... local hospitals. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO ) ... American Red Cross Blood Services Penn-Jersey Region earlier today. ...
... The Cancer Center at Harrington has received ... , "We expect to start seeing patients immediately," said Diane ... approval was granted today by the Massachusetts Department of Public ... , The opening of The Cancer Center at Harrington ...
... BEIJING, Dec. 3 /PRNewswire-Asia/ -- Long believed to ... important ingredients in global,cuisine, has seen increased demand in China ... timing of this ginger demand increase coincides with supply shortages,effecting ... about,a potential repeat of the current demand hysteria over garlic. ...
... SILVER SPRING, Md., Dec. 3 We are closer than ... affordable, quality care for all. The American Nurses Association ... support for meaningful health care reform. , See video from ... for a health care system that focuses on wellness and ...
Cached Medicine News:Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 2Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 3Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 4Health News:Orthotics And Beyond Introduces Compressive Cold Therapy Products for Plantar Fasciitis Treatment 2Health News:American Red Cross Wins Court Injunction Against Striking Teamsters 2Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2
The incorporation of a reverse osmosis (RO) system and an ultrapure water system into a single stand-alone tower provides numerous benefits to the busy laboratory....
... systems produce ultrapure water from pre-treated water at ... to meet the basic needs of scientific laboratories. ... lamp (185 nm and 254 nm) to produce ... 5 ppb TOC when fed by Elix water). ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... Built-in, motor-driven internal calibration mass for ...
... UniBloc weighing mechanism for speed, stability ... control, analog display modes, multiple units ... measure functions, auto print, and GLP/GMP/ISO ... from built-in clock. Built-in, motor-driven ...
Medicine Products: